Teaming collaborations between diverse innovators are encouraged to help advance the development of a single-administration pandemic influenza A(H5N1) vaccine. Entrants interested in forming teams can fill out the teaming form to share a participant profile and connect with potential collaborators.

Entrant profiles will be available on this page for those looking to connect with others in the field. The page will be updated regularly throughout the open submissions period.

Teams

Select All That Apply

VisMederi America Corp.

Cleveland, OH

My team specializes in

Other

Summary of core technology or service

Pre-clinical services to include immunogenicity and efficacy evaluations Bioanalytical support using validated influenza assays for pre-clinical and clinical studies

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENTNOVEL DELIVERY SYSTEMSADJUVANTS

Contact

Brian Price

Role

President

Photosynthetic B.V.

Amsterdam, The Netherlands

My team specializes in

Novel delivery systemsOther

Summary of core technology or service

Photosynthetic develops a high-resolution volumetric printing platform for rapid microfabrication. The technology enables complex polymer microstructures, including microneedle arrays and other vaccine-delivery components, with micron-scale precision

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

EXCIPIENTSANTIGEN DEVELOPMENTADJUVANTS

Contact

Magdalena Kurzyp

Role

CBO

Contact email address

magdalena@photosynthetic.nl

Vaxine Inc

Colorado

My team specializes in

AdjuvantsAntigen developmentNovel delivery systems

Summary of core technology or service

Vaxine specialises in development of new adjuvants targetting DC-SIGN (Advax delta inulin adjuvant), TLR9 (CpG55.2) as well as having candidate compounds targeting TLR2, TLR4, TLR7/8 and NOD2. It also has expertise in antigen design and delivery.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

NOVEL DELIVERY SYSTEMSANTIGEN DEVELOPMENT

Contact

Nikolai Petrovsky

Role

Research Director

Contact email address

nikolai.petrovsky@vaxine.net

Website

vaxine.net

Texas Children's Ctr for Vaccine Development, Baylor College Med

Houston, TX, USA

My team specializes in

Antigen developmentOtherAdjuvants

Summary of core technology or service

We develop recombinant protein vaccines against viruses, with experience in technology transfer, QA/RA systems, and IND submissions to the US FDA supporting translation from discovery through clinical readiness.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ADJUVANTSANTIGEN DEVELOPMENTEXCIPIENTSNOVEL DELIVERY SYSTEMS

Contact

Ulrich Strych

Role

Director for Strategic Initiatives and Program Development

Contact email address

strych@bcm.edu

Vaxxas Pty Ltd

Brisbane, Queensland, Australia

My team specializes in

Novel delivery systems

Summary of core technology or service

The high-density microarray patch (HD-MAP) is a needle-free vaccine delivery platform for skin-based vaccine delivery. Potential benefits: enhanced immune response, antigen dose-sparing, improved thermostability, and simplified administration.

The earliest stage My team is interested in submitting to

STAGE 0: CONCEPT STAGE

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Elouise Comber

Role

Business Development

Contact email address

ecomber@vaxxas.com

DEKA

Manchester, NH

My team specializes in

Novel delivery systems

Summary of core technology or service

Self-administrable, intradermal vaccine applicator

The earliest stage My team is interested in submitting to

STAGE 1: NONCLINICAL PROOF OF CONCEPT

We are interested in partnerships with entities specializing in

ANTIGEN DEVELOPMENT

Contact

Fareena

Role

VP - Strategy & Commercialization

Contact email address

fareena@dekaresearch.com